# US 8,771,692 B2 · Methods for treatment of muscular dystrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,692 B2
- Document ID: US8771692B2
- Status: Granted
- Kind: B2
- Application number: 13/380,489
- Filed: 2010-07-02
- Published: 2012-06-28
- Granted: 2014-07-08
- Earliest claimed: 2009-07-02
- Assignees: FibroGen, Inc.
- Applicants: Enrique Brandan; Roel Goldschmeding; Noelynn A. Oliver
- Inventors: Enrique Brandan; Roel Goldschmeding; Noelynn A. Oliver
- Web page: https://patentgrep.com/patent/US8771692B2

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.

## Claims

### Claim 1

A method for increasing muscle strength in a subject having muscular dystrophy, the method comprising administering to the subject a therapeutically effective amount of an anti-connective tissue growth factor (CTGF) antibody or fragment thereof, thereby increasing muscle strength.

### Claim 2 (depends on 1)

The method of claim 1, wherein muscular dystrophy is selected from the group consisting of Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-CTGF antibody is a monoclonal antibody or a fragment thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-CTGF monoclonal antibody is CLN-1, or a fragment thereof.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering an angiotensin receptor blocker, a statin, a calcium channel blocker, a beta-blocker, a glucocorticoid, an advanced glycation endproduct inhibitor or a diuretic.

### Claim 7

A method for increasing the maximal force or tetanus strength of muscle in a subject having muscular dystrophy, the method comprising administering to the subject a therapeutically effective amount of an anti-CTGF antibody or fragment thereof, thereby increasing the maximal force or tetanus strength of muscle.

### Claim 8 (depends on 7)

The method of claim 7, wherein muscular dystrophy is selected from the group consisting of Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.

### Claim 9 (depends on 7)

The method of claim 7, wherein the subject is human.

### Claim 10 (depends on 7)

The method of claim 7, wherein the anti-CTGF antibody is a monoclonal antibody or a fragment thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the anti-CTGF monoclonal antibody is CLN-1, or a fragment thereof.

### Claim 12 (depends on 7)

The method of claim 7, further comprising administering an angiotensin receptor blocker, a statin, a calcium channel blocker, a beta-blocker, a glucocorticoid, an advanced glycation endproduct inhibitor or a diuretic.